- Home
- RENB vs GANX Comparison
RENB vs GANX Comparison
Compare RENB & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- GANX
- Stock Information
- Founded
- RENB 2011
- GANX 2017
- Country
- RENB United States
- GANX United States
- Employees
- RENB N/A
- GANX N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- RENB Health Care
- GANX Health Care
- Exchange
- RENB Nasdaq
- GANX Nasdaq
- Market Cap
- RENB 62.0M
- GANX 53.8M
- IPO Year
- RENB N/A
- GANX 2021
- Fundamental
- Price
- RENB $0.28
- GANX $1.64
- Analyst Decision
- RENB
- GANX Strong Buy
- Analyst Count
- RENB 0
- GANX 5
- Target Price
- RENB N/A
- GANX $8.20
- AVG Volume (30 Days)
- RENB 8.2M
- GANX 316.1K
- Earning Date
- RENB 05-15-2025
- GANX 08-07-2025
- Dividend Yield
- RENB N/A
- GANX N/A
- EPS Growth
- RENB N/A
- GANX N/A
- EPS
- RENB N/A
- GANX N/A
- Revenue
- RENB N/A
- GANX N/A
- Revenue This Year
- RENB N/A
- GANX N/A
- Revenue Next Year
- RENB N/A
- GANX N/A
- P/E Ratio
- RENB N/A
- GANX N/A
- Revenue Growth
- RENB N/A
- GANX N/A
- 52 Week Low
- RENB $0.27
- GANX $0.89
- 52 Week High
- RENB $2.10
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- RENB 38.32
- GANX 40.97
- Support Level
- RENB $0.33
- GANX $1.65
- Resistance Level
- RENB $0.37
- GANX $2.04
- Average True Range (ATR)
- RENB 0.04
- GANX 0.16
- MACD
- RENB -0.01
- GANX -0.01
- Stochastic Oscillator
- RENB 6.24
- GANX 17.21
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.